Microbot Medical Inc MBOT 深 滬
已收盤 05-22 16:00:00 美东时间
1.71
-0.070
-3.93%
華盛通- 最 高1.805
- 今 開1.76
- 成交量 129.07万股
- 最 低 1.70
- 昨 收 1.78
- 總市值 1.15亿
- 52周最高 4.67
- 市盈率 靜 --
- 換手率 1.92%
- 52周最低 1.6001
- 委 比 -1.38%
- 總股本 6716.48万
- 歷史最高 149.10
- 量 比 0.72
- 振 幅 5.90%
- 歷史最低 0.82
- 每 手 1
- 風險率 0.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Watching Microbot Medical; Shares See Volume To The Downside; White Diamond Research Issues Report On Co
https://whitediamondresearch.com/research/we-interviewed-some-of-the-first-surgeons-to-use-microbot-medicals-liberty-endovascular-robotic-system-and-its-clear-that-it-will-be-a-commercial-failure-1-price-target/
05-14 21:37
Microbot Medical Announces LIBERTY System Gains Clinical Validation And Early Commercial Adoption As Global Expansion Accelerates
Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings to everyday practiceThe Company will attend the Annual Global Embolization
05-05 20:38
美股大行评级 | 小摩上调Bloom Energy目标价从166美元升至231美元；目标价28美元！大摩、高盛等多家机构首予Janus Living(JAN)超配评级
今日重点评级关注：Ascendiant Capital：维持Banzai International"买入"评级，目标价从23美元升至24美元；Ascendiant Capital：维持Synergy CHC Corp."买入"评级，目标价从5美元升至5.5美元
04-15 11:31
Microbot Medical Entered ATM Agreement With H.C. Wainwright & Co; May Offer & Sell Up To $39.2M
-SEC Filing
04-11 05:36
Microbot Medical Q4 EPS $(0.04) Beats $(0.06) Estimate
Microbot Medical (NASDAQ:MBOT) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 78.95 percent increase over losses of $(0.19) per share from
03-27 05:47
Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System
Emory Healthcare successfully performed robotic prostate artery embolization (PAE) and Y-90 radioembolization for liver cancer using Microbot Medical's LIBERTY System, a first-of-its-kind FDA-cleared, single-use robotic platform. The system enhances precision, efficiency, and safety in minimally invasive endovascular procedures, addressing conditions like benign prostatic hyperplasia (BPH) and liver cancer.
03-26 12:30
Microbot Medical publishes ACCESS-PVI pivotal study on LIBERTY system in JVIR
Microbot Medical publishes ACCESS-PVI pivotal study on LIBERTY system in JVIR Microbot Medical reported that an article on its ACCESS-PVI multicenter feasibility study of the LIBERTY endovascular robotic system was published in the Journal of Vascular and Interventional Radiology. The study was comp
03-24 20:30
Microbot Medical to Present at Roth Annual Growth Conference
Microbot Medical to Present at Roth Annual Growth Conference Microbot Medical will participate in the Roth Annual Growth Conference on March 22-24, 2026 in Laguna Niguel, California. CEO Harel Gadot is scheduled to present in a fireside Q&A at 4:00 pm PT on March 23, 2026. The release is available a
03-17 20:40
Microbot Medical® to Participate at the 38th Annual Roth Conference
Microbot Medical Inc. will present at the Roth Annual Growth Conference on March 22-24, 2026, with CEO Harel Gadot discussing the LIBERTY® Endovascular Robotic System. The live fireside Q&A on March 23 at 4:00 PM PT will highlight the system's unique features and market progress. LIBERTY, the first FDA-cleared, single-use robotic system for endovascular procedures, aims to enhance safety and efficiency. The company plans a full market release in ...
03-17 12:40
Microbot Medical Commends American Medical Association's Expanding Efforts To Protect Health Care Professionals From Ionizing Radiation
Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, commends the American Medical Association's (AMA) expanding efforts to protect health care
03-04 21:34
